| Literature DB >> 24840575 |
Hui Wang1, Zhiyun Du2, Changyuan Zhang3, Zhikai Tang4, Yan He5, Qiuyan Zhang6, Jun Zhao7, Xi Zheng8.
Abstract
Aldehyde dehydrogenase 1 (ALDH1) is reported as a biomarker for identifying some cancer stem cells, and down-regulation or inhibition of the enzyme can be effective in anti-drug resistance and a potent therapeutic for some tumours. In this paper, the inhibitory activity, mechanism mode, molecular docking and 3D-QSAR (three-dimensional quantitative structure activity relationship) of curcumin analogues (CAs) against ALDH1 were studied. Results demonstrated that curcumin and CAs possessed potent inhibitory activity against ALDH1, and the CAs compound with ortho di-hydroxyl groups showed the most potent inhibitory activity. This study indicates that CAs may represent a new class of ALDH1 inhibitor.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24840575 PMCID: PMC4057759 DOI: 10.3390/ijms15058795
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
The structures and bioactivity values of activity of curcumin derivatives.
|
| ||||||
|---|---|---|---|---|---|---|
| Compounds | X | R1 | R2 | R3 | IC50 μmol/L | pIC50 |
| 1-(4-Br-2-F)4-piperidinone | OCH3 | OH | OCH3 | 31.2 | 4.51 | |
| 1-(4-Br-2-F)4-piperidinone | OH | OH | H | 33.5 | 4.47 | |
| 4-piperidinone | OCH3 | OH | OCH3 | 30.0 | 4.52 | |
| 4-piperidinone | OH | OH | H | 39.4 | 4.40 | |
| Acetone | OH | OH | H | 23.6 | 4.63 | |
| cyclopentanone | OH | OH | H | 3.41 | 5.46 | |
| cyclohexanone | OH | OH | H | 6.5 | 5.20 | |
| tetrahydropyran-4-ones | OH | OH | H | 7.9 | 5.10 | |
| tetrahydrothiopyran-4-one | OH | OH | H | 22.7 | 4.64 | |
| cyclopentanone | H | OH | H | 54.2 | 4.20 | |
| tetrahydropyran-4-ones | H | OH | H | 39.7 | 4.41 | |
| cyclopentanone | OH | H | OH | 43.2 | 4.36 | |
| cyclopentanone | OCH3 | OH | H | 24.2 | 4.62 | |
| tetrahydrothiopyran-4-one | OCH3 | OH | H | 31.3 | 4.50 | |
| tetrahydropyran-4-ones | OCH3 | OH | OCH3 | 16.6 | 4.78 | |
| tetrahydropyran-4-ones | OCH3 | OH | F | 53.2 | 4.27 | |
| Acetone | Br | OH | Br | 25.8 | 4.59 | |
| cyclohexanone | Br | OH | Br | 17.5 | 4.76 | |
| tetrahydropyran-4-ones | Br | OH | Br | 18.7 | 4.73 | |
| tetrahydrothiopyran-4-one | Br | OH | Br | 17.7 | 4.75 | |
| tetrahydrothiopyran-4-one | OCH3 | OCH3 | OCH3 | 63.1 | 4.20 | |
| cyclohexanone | H | N(CH3)2 | H | 73.5 | 4.13 | |
| tetrahydrothiopyran-4-one | H | N(CH3)2 | H | 69.4 | 4.16 | |
| cyclohexanone | H | Br | H | 8.20 | 5.08 | |
|
| ||||||
|
| ||||||
|
| ||||||
| Cyclopentanone |
| 30.1 | 4.53 | |||
| tetrahydrothiopyran-4-one |
| 10.6 | 4.97 | |||
| cyclohexanone |
| 63.2 | 4.22 | |||
| Cyclohexanone |
| 73.4 | 4.13 | |||
| Cyclopentanone |
| 13.7. | 4.86 | |||
| Cyclohexanone |
| 18.4 | 4.74 | |||
| Curcumin | 36.9 | 4.43 | ||||
| Disufiram | 2.91 | 5.54 | ||||
Figure 1.Lineweaver–Burk plots for inhibition of compound 6 and compound 24 against aldehyde dehydrogenase 1 (ALDH1) for the catalysis of propanal.
Summary of the partial-least-squares for the CoMFA/CoMSIA models.
| Statistical | Field Contribution | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| S | E | H | D | A | ||||||
| CoMFA | 0.606 | 9 | 0.999 | 0.011 | 2577.847 | 0.552 | 0.448 | |||
| CoMFA | 0.597 | 8 | 0.998 | 0.018 | 990.030 | 0.554 | 0.446 | |||
| SE | 0.608 | 9 | 0.999 | 0.082 | 1924.926 | 0.386 | 0.614 | |||
| SHE | 0.434 | 6 | 0.945 | 0.045 | 93.12 | 0.294 | 0.420 | 0.287 | ||
| SED | 0.56 | 6 | 0.987 | 0.031 | 210.105 | 0.287 | 0.3785 | 0.338 | ||
| SEA | 0.443 | 3 | 0.848 | 0.134 | 40.891 | 0.27 | 0.388 | 0.342 | ||
| SEHD | 0.477 | 3 | 0.902 | 0.107 | 67.688 | 0.219 | 0.305 | 0.182 | 0.293 | |
| SEDA | 0.484 | 5 | 0.968 | 0.064 | 121.317 | 0.207 | 0.295 | 0.301 | 0.197 | |
| SEHA | 0.383 | 3 | 0.862 | 0.128 | 45.79 | 0.207 | 0.319 | 0.196 | 0.278 | |
| SEHDA | 0.421 | 4 | 0.945 | 0.083 | 89.839 | 0.166 | 0.269 | 0.139 | 0.247 | 0.179 |
q, Crossvalidated correlation coefficient using leave-one-out procedure; N, optimal number of principal components; r, non cross validated correlation coefficient; F: F-test value; Steric (S) and Electrostatic (E) field from CoMFA; Steric (S), Eectrostatic (E), Hydrophobic (H), Donor (D), and Acceptor (A) fields from CoMSIA.
(CoMFA)/(CoMSIA) predicted activity (pIC50) of compounds.
| Compounds | Actual | CoMFA | CoMSIA | ||
|---|---|---|---|---|---|
|
|
| ||||
| Predicted | Residues | Predicted | Residues | ||
| 4.51 | 4.533 | −0.023 | 4.540 | −0.030 | |
| 4.47 | 4.466 | 0.004 | 4.431 | 0.039 | |
| 4.52 | 4.503 | 0.017 | 4.546 | −0.026 | |
| 4.40 | 4.418 | −0.018 | 4.433 | −0.033 | |
| 4.63 | 4.704 | −0.074 | 4.630 | 0.000 | |
| 5.34 | 5.341 | −0.001 | 5.360 | −0.020 | |
| 5.20 | 5.107 | 0.093 | 5.109 | 0.091 | |
| 5.10 | 5.095 | 0.005 | 5.102 | −0.002 | |
| 4.64 | 4.763 | −0.123 | 4.894 | −0.254 | |
| 4.20 | 4.557 | −0.357 | 4.404 | −0.204 | |
| 4.41 | 4.503 | −0.093 | 4.542 | −0.132 | |
| 4.36 | 4.318 | 0.042 | 4.333 | 0.027 | |
| 4.62 | 4.674 | −0.054 | 4.528 | 0.092 | |
| 4.50 | 4.483 | 0.017 | 4.533 | −0.033 | |
| 4.78 | 4.556 | 0.224 | 4.919 | −0.139 | |
| 4.27 | 4.307 | −0.037 | 4.277 | −0.007 | |
| 4.59 | 4.632 | −0.042 | 4.598 | −0.008 | |
| 4.76 | 4.825 | −0.065 | 4.754 | 0.006 | |
| 4.73 | 4.672 | 0.058 | 4.733 | −0.003 | |
| 4.75 | 4.705 | 0.045 | 4.683 | 0.067 | |
| 4.20 | 4.138 | 0.062 | 4.804 | −0.604 | |
| 4.13 | 4.154 | −0.024 | 4.133 | −0.003 | |
| 4.16 | 4.152 | 0.008 | 4.124 | 0.036 | |
| 5.08 | 4.965 | 0.115 | 4.746 | 0.334 | |
| 4.53 | 4.540 | −0.01 | 4.646 | −0.116 | |
| 4.97 | 4.885 | 0.085 | 4.685 | 0.285 | |
| 4.22 | 4.199 | 0.021 | 4.202 | 0.018 | |
| 4.13 | 4.103 | 0.027 | 4.131 | −0.001 | |
| 4.86 | 4.825 | 0.035 | 4.885 | −0.025 | |
| 4.74 | 4.709 | 0.031 | 4.808 | −0.068 | |
Test set.
Figure 2.(A) The experimental and Predicted activities of CoMFA; (B) The experimental and Predicted activities of CoMSIA.
Figure 3.CoMFA steric filed (A) and electrostatic field (B). S fields: favored (green) and disfavored (yellow); E fields: electropositive (blue) and electronegative (red).
Figure 4.CoMSIA steric filed (A) and electrostatic field (B); CoMSIA Hydrogen bond donor (C). S fields: favored (green) and disfavored (yellow); E fields: Lipophilic (blue) and hydrophobic (red); D field: favored (purple) and disfavored (cyan).
Figure 5.The binding mode between compound 6 with ALDH1 (A). Active site MOLCAD surface representation Liphilic potential (B) and Hydrogen Bonding (C); (B) Brown: Hydrogen and green: Hydrophlic; (C) Red: Hydrogen donor and blue: Hydrogen acceptor.
Figure 6.The binding mode between curcumin with ALDH1(A). Active site MOLCAD surface representation Liphilic potential and Hydrogen Bonding; (B) Brown: Hydrogen and green: Hydrophlic; (C) Red: Hydrogen donor and blue: Hydrogen acceptor).
Designed molecules and predicted pIC50 values of ALDH1 inhibitors.
| (a) | (b) | (c) | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
|
|
|
| |||||||
|
| |||||||||
| Compound | Tail | R1 | R2 | R3 | R4 | R5 | R6 | Predict pIC50 | |
|
| |||||||||
| CoMFA | CoMSIA | ||||||||
| a | H | OH | H | H | OCH3 | H | 5.016 | 4.858 | |
| a | H | OH | H | H | OCH3 | OCH3 | 5.868 | 6.124 | |
| a | H | OH | H | OCH3 | OCH3 | OCH3 | 5.997 | 6.077 | |
| a | OH | OH | H | H | OCH3 | H | 6.173 | 5.766 | |
| a | OH | OH | H | OCH3 | OCH3 | H | 5.815 | 6.096 | |
| a | OH | OH | H | OCH3 | OCH3 | OCH3 | 5.689 | 5.966 | |
| a | H | Br | H | H | OCH3 | H | 5.542 | 6.079 | |
| a | H | Br | H | OCH3 | OCH3 | H | 5.689 | 5.993 | |
| a | H | Br | H | OCH3 | OCH3 | OCH3 | 5.257 | 5.857 | |
| b | H | OH | H | H | OCH3 | H | 5.687 | 6.100 | |
| b | H | OH | H | H | OCH3 | OCH3 | 5.974 | 6.240 | |
| b | H | OH | H | OCH3 | OCH3 | OCH3 | 5.370 | 5.725 | |
| b | OH | OH | H | H | OCH3 | H | 6.062 | 6.127 | |
| b | OH | OH | H | OCH3 | OCH3 | H | 6.034 | 6.332 | |
| b | OH | OH | H | OCH3 | OCH3 | OCH3 | 5.141 | 5.739 | |
| b | H | Br | H | H | OCH3 | H | 6.116 | 6.031 | |
| b | H | Br | H | OCH3 | OCH3 | H | 6.061 | 5.991 | |
| b | H | Br | H | OCH3 | OCH3 | OCH3 | 5.089 | 5.859 | |
| c | H | OH | H | H | OCH3 | H | 4.800 | 4.785 | |
| c | H | OH | H | H | OCH3 | OCH3 | 6.109 | 6.199 | |
| c | H | OH | H | OCH3 | OCH3 | OCH3 | 5.961 | 5.926 | |
| c | OH | OH | H | H | OCH3 | H | 6.097 | 6.077 | |
| c | OH | OH | H | OCH3 | OCH3 | H | 6.062 | 5.914 | |
| c | OH | OH | H | OCH3 | OCH3 | OCH3 | 5.753 | 5.914 | |
| c | H | Br | H | H | OCH3 | H | 6.168 | 6.128 | |
| c | H | Br | H | OCH3 | OCH3 | H | 6.104 | 6.253 | |
| c | H | Br | H | OCH3 | OCH3 | OCH3 | 6.028 | 5.842 | |
Figure 7.Molecular alignment of the compounds in the training set.
Figure 8.Molecular skeleton region.